Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer

Najiba Chargi, Fereshta Bashiri, Anne W. Wendrich, Ernst J. Smid, Pim A. de Jong, Alwin D.R. Huitema, Lot A. Devriese, Remco de Bree

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

3 Citaten (Scopus)

Samenvatting

Purpose: Evidence suggests that patients’ skeletal muscle mass (SMM) can predict the patients at risk for cisplatin dose-limiting toxicities (DLT). Cisplatin is currently dosed on body surface area (BSA). The predictive value of SMM for cisplatin DLT in patients with locally advanced head and neck cancer (LA-HNC) is investigated. Methods: Patients with LA-HNC treated with cisplatin-based chemoradiotherapy (CRT) were included. SMM was measured using pre-treatment scans. Logistic regression analysis was performed to identify the predictive impact of low SMM for DLT. Results: In total, 343 patients were included of which 199 patients (58.0%) had low SMM and 154 patients (44.9%) experienced cisplatin DLT. In multivariate analysis, low SMM at diagnosis was the only predictive factor for DLT (HR 1.8, 95% CI 1.1–2.9). Conclusions: Low SMM was associated with an increased risk of DLT. Trials are needed to investigate cisplatin dosing with consideration of SMM rather than solely BSA.

Originele taal-2Engels
Pagina's (van-tot)3685-3694
Aantal pagina's10
TijdschriftEuropean Archives of Oto-Rhino-Laryngology
Volume279
Nummer van het tijdschrift7
DOI's
StatusGepubliceerd - jul. 2022
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer'. Samen vormen ze een unieke vingerafdruk.

Citeer dit